Condition: NK-Cell Lymphoma · NK-Cell Leukemia · Peripheral T Cell Lymphoma · Sponsor: New York Medical College
Patients are in 2 cohorts: Cohort 1: dexamethasone, methotrexate, ifosfamide, pegaspargase, and etoposide (modified SMILE) chemotherapy regimen alone and pembrolizumab in children, adolescents, and young adults with advanced stage NK lymphoma and leukemia Cohort 2: combining pralatrexate (PRX) (Cycles 1, 2, 4, 6) and brentuximab vedotin (BV) (Cycles 3, 5) to cyclophosphamide, doxorubicin, and prednisone in children, adolescent, and young adults with advanced peripheral T-cell lymphoma (non-anaplastic large cell lymphoma or non-NK lymphoma/leukemia) . Both groups proceed to allogeneic stem cell transplant with disease response.
This description comes directly from the study's public registry record.
Ana Xavier · (205) 638-6763 · axavier@peds.uab.edu
Lauren Harrison · 6172857844 · lauren_harrison@nymc.edu
Always discuss trial participation with your own doctor first.
| University of Alabama | Birmingham, Alabama, United States | Recruiting |
| Children's Hospital Orange County | Orange, California, United States | Recruiting |
| University of California San Francisco | San Francisco, California, United States | Recruiting |
| Helen De Vos | Grand Rapids, Michigan, United States | Recruiting |
| New York Medical College | Valhalla, New York, United States | Recruiting |
| Nationwide Children's Hospital | Columbus, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03719105